Cybin Inc. Common Stock Total Assets
Cybin Inc. Common Stock total assets. Based on the latest financial reports, Cybin Inc. Common Stock (HELP) holds total assets worth $398.07 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Cybin Inc. Common Stock (HELP) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Cybin Inc. Common Stock (2017–2025)
Total assets of Cybin Inc. Common Stock from 2017 to 2025. This chart illustrates how Cybin Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See Cybin Inc. Common Stock (HELP) share price today for real-time trading data and today's change.
Cybin Inc. Common Stock - Asset Composition Analysis
Cybin Inc. Common Stock Total Assets Breakdown (March 2025)
Cybin Inc. Common Stock total assets breakdown as of March 2025. Cybin Inc. Common Stock's total assets of $398.07 Million consist of 64.2% current assets and 35.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 52.2% |
| Accounts Receivable | $5.88 Million | 2.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $41.02 Million | 15.9% |
| Goodwill | $51.49 Million | 19.9% |
Asset Composition Trend (2017–2025)
This chart illustrates how Cybin Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Cybin Inc. Common Stock working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cybin Inc. Common Stock's current assets represent 64.2% of total assets in 2025, a decrease from 97.7% in 2017.
- Cash Position: Cash and equivalents constituted 52.2% of total assets in 2025, down from 97.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 19.9% of total assets.
Cybin Inc. Common Stock Competitors by Total Assets
Key competitors of Cybin Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Cybin Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.78 | 12.60 | 13.57 |
| Quick Ratio | 13.78 | 12.60 | 13.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $283.64 Million | $154.38 Million | $61.58 Million |
Cybin Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Cybin Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.96 |
| Latest Market Cap to Assets Ratio | 0.90 |
| Asset Growth Rate (YoY) | -14.4% |
| Total Assets | $258.62 Million |
| Market Capitalization | $233.50 Million USD |
Valuation Analysis
Near Book Valuation: The market values Cybin Inc. Common Stock's assets close to their book value (0.90x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Cybin Inc. Common Stock's assets decreased by 14.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cybin Inc. Common Stock (2017–2025)
The table below shows the annual total assets of Cybin Inc. Common Stock from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $258.62 Million | -14.37% |
| 2024-03-31 | $302.02 Million | +460.37% |
| 2023-03-31 | $53.90 Million | -35.88% |
| 2022-03-31 | $84.06 Million | -8.74% |
| 2021-03-31 | $92.11 Million | +5283.52% |
| 2020-03-31 | $1.71 Million | +318.97% |
| 2019-03-31 | $408.38K | -10.48% |
| 2018-03-31 | $456.18K | +2.96% |
| 2017-03-31 | $443.08K | -- |
About Cybin Inc. Common Stock
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical tr… Read more